


## WHAT IS CLAIMED IS:

1. A compound having the formula:



or a pharmaceutically acceptable salt or N-oxide thereof, wherein

the subscript  $n$  is an integer of from 1 to 2;

the subscript  $m$  is an integer of from 0 to 10;

each  $\text{R}^1$  is a substituent independently selected from the group consisting of  $\text{C}_{1-8}$  alkyl,

$\text{C}_{1-8}$  haloalkyl,  $\text{C}_{3-6}$  cycloalkyl,  $\text{C}_{2-8}$  alkenyl,  $\text{C}_{2-8}$  alkynyl,  $-\text{COR}^a$ ,  $-\text{CO}_2\text{R}^a$ ,

$-\text{CONR}^a\text{R}^b$ ,  $-\text{NR}^a\text{COR}^b$ ,  $-\text{SO}_2\text{R}^a$ ,  $-\text{X}^1\text{COR}^a$ ,  $-\text{X}^1\text{CO}_2\text{R}^a$ ,  $-\text{X}^1\text{CONR}^a\text{R}^b$ ,

$-\text{X}^1\text{NR}^a\text{COR}^b$ ,  $-\text{X}^1\text{SO}_2\text{R}^a$ ,  $-\text{X}^1\text{SO}_2\text{NR}^a\text{R}^b$ ,  $-\text{X}^1\text{NR}^a\text{R}^b$ ,  $-\text{X}^1\text{OR}^a$ , wherein  $\text{X}^1$  is a

member selected from the group consisting of  $\text{C}_{1-4}$  alkylene,  $\text{C}_{2-4}$  alkenylene and

$\text{C}_{2-4}$  alkynylene and each  $\text{R}^a$  and  $\text{R}^b$  is independently selected from the group

consisting of hydrogen,  $\text{C}_{1-8}$  alkyl,  $\text{C}_{1-8}$  haloalkyl,  $\text{C}_{3-6}$  cycloalkyl and aryl-

$\text{C}_{1-4}$ alkyl, and wherein the aliphatic portions of each of said  $\text{R}^1$  substituents is

optionally substituted with from one to three members selected from the group

consisting of  $-\text{OH}$ ,  $-\text{OR}^m$ ,  $-\text{OC}(\text{O})\text{NHR}^m$ ,  $-\text{OC}(\text{O})\text{N}(\text{R}^m)_2$ ,  $-\text{SH}$ ,  $-\text{SR}^m$ ,  $-\text{S}(\text{O})\text{R}^m$ ,

$-\text{S}(\text{O})_2\text{R}^m$ ,  $-\text{SO}_2\text{NH}_2$ ,  $-\text{S}(\text{O})_2\text{NHR}^m$ ,  $-\text{S}(\text{O})_2\text{N}(\text{R}^m)_2$ ,  $-\text{NHS}(\text{O})_2\text{R}^m$ ,  $-\text{NR}^m\text{S}(\text{O})_2\text{R}^m$ ,

$-\text{C}(\text{O})\text{NH}_2$ ,  $-\text{C}(\text{O})\text{NHR}^m$ ,  $-\text{C}(\text{O})\text{N}(\text{R}^m)_2$ ,  $-\text{C}(\text{O})\text{R}^m$ ,  $-\text{NHC}(\text{O})\text{R}^m$ ,  $-\text{NR}^m\text{C}(\text{O})\text{R}^m$ ,

$-\text{NHC}(\text{O})\text{NH}_2$ ,  $-\text{NR}^m\text{C}(\text{O})\text{NH}_2$ ,  $-\text{NR}^m\text{C}(\text{O})\text{NHR}^m$ ,  $-\text{NHC}(\text{O})\text{NHR}^m$ ,

$-\text{NR}^m\text{C}(\text{O})\text{N}(\text{R}^m)_2$ ,  $-\text{NHC}(\text{O})\text{N}(\text{R}^m)_2$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{R}^m$ ,  $-\text{NHCO}_2\text{R}^m$ ,  $-\text{NR}^m\text{CO}_2\text{R}^m$ ,

$-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{NHR}^m$ ,  $-\text{N}(\text{R}^m)_2$ ,  $-\text{NR}^m\text{S}(\text{O})\text{NH}_2$  and  $-\text{NR}^m\text{S}(\text{O})_2\text{NHR}^m$ ,

wherein each  $\text{R}^m$  is independently an unsubstituted  $\text{C}_{1-6}$  alkyl;

$\text{Ar}^1$  is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrazinyl,

pyridazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl and purinyl, each of

which is optionally substituted with from one to five  $\text{R}^2$  substituents

independently selected from the group consisting of halogen,  $-\text{OR}^c$ ,  $-\text{OC}(\text{O})\text{R}^c$ ,  $-\text{NR}^c\text{R}^d$ ,

$-\text{SR}^c$ ,  $-\text{R}^c$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{CO}_2\text{R}^c$ ,  $-\text{CONR}^c\text{R}^d$ ,  $-\text{C}(\text{O})\text{R}^c$ ,  $-\text{OC}(\text{O})\text{NR}^c\text{R}^d$ ,  $-\text{NR}^d\text{C}(\text{O})\text{R}^c$ ,

$-\text{NR}^d\text{C}(\text{O})_2\text{R}^c$ ,  $-\text{NR}^c-\text{C}(\text{O})\text{NR}^c\text{R}^d$ ,  $-\text{NH}-\text{C}(\text{NH}_2)=\text{NH}$ ,

$-\text{NR}^c\text{C}(\text{NH}_2)=\text{NH}$ ,  $-\text{NH}-\text{C}(\text{NH}_2)=\text{NR}^c$ ,  $-\text{NH}-\text{C}(\text{NHR}^c)=\text{NH}$ ,  $-\text{S}(\text{O})\text{R}^c$ ,  $-\text{S}(\text{O})_2\text{R}^c$ ,  $-\text{NR}^c\text{S}(\text{O})_2\text{R}^c$ ,

$-\text{S}(\text{O})_2\text{NR}^c\text{R}^d$ ,  $-\text{N}_3$ ,  $-\text{X}^2\text{OR}^c$ ,  $-\text{O}-\text{X}^2\text{OR}^c$ ,  $-\text{X}^2\text{OC}(\text{O})\text{R}^c$ ,  $-\text{X}^2\text{NR}^c\text{R}^d$ ,

$-\text{O}-\text{X}^2\text{NR}^c\text{R}^d$ ,  $-\text{X}^2\text{SR}^c$ ,  $-\text{X}^2\text{CN}$ ,  $-\text{X}^2\text{NO}_2$ ,  $-\text{X}^2\text{CO}_2\text{R}^c$ ,  $-\text{O}-\text{X}^2\text{CO}_2\text{R}^c$ ,  $-\text{X}^2\text{CONR}^c\text{R}^d$ ,

$-O-X^2CONR^cR^d$ ,  $-X^2C(O)R^c$ ,  $-X^2OC(O)NR^cR^d$ ,  $-X^2NR^dC(O)R^c$ ,  $-X^2NR^dC(O)_2R^c$ ,  
 $-X^2NR^cC(O)NR^cR^d$ ,  $-X^2NH-C(NH_2)=NH$ ,  $-X^2NR^cC(NH_2)=NH$ ,  $-X^2NH-$   
 $C(NH_2)=NR^c$ ,  $-X^2NH-C(NHR^c)=NH$ ,  $-X^2S(O)R^c$ ,  $-X^2S(O)_2R^c$ ,  $-X^2NR^cS(O)_2R^c$ ,  
 $-X^2S(O)_2NR^cR^d$ ,  $-X^2N_3$ ,  $-NR^d-X^2OR^c$ ,  $-NR^d-X^2NR^cR^d$ ,  $-NR^d-X^2CO_2R^c$ , and  
 $-NR^d-X^2CONR^cR^d$ , wherein  $X^2$  is a member selected from the group consisting of  
 $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene and  $C_{2-4}$  alkynylene and each  $R^c$  and  $R^d$  is  
independently selected from hydrogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  
 $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl,  
or optionally  $R^c$  and  $R^d$  when attached to the same nitrogen atom can be combined  
with the nitrogen atom to form a five or six-membered ring having from 0 to 2  
additional heteroatoms as ring members; and each  $R^e$  is independently selected  
from the group consisting of  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-8}$   
alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl, and  
each of  $R^c$ ,  $R^d$  and  $R^e$  is optionally further substituted with from one to three  
members selected from the group consisting of  $-OH$ ,  $-OR^n$ ,  $-OC(O)NHR^n$ ,  
 $-OC(O)N(R^n)_2$ ,  $-SH$ ,  $-SR^n$ ,  $-S(O)R^n$ ,  $-S(O)_2R^n$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^n$ ,  
 $-S(O)_2N(R^n)_2$ ,  $-NHS(O)_2R^n$ ,  $-NR^nS(O)_2R^n$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^n$ ,  $-C(O)N(R^n)_2$ ,  
 $-C(O)R^n$ ,  $-NHC(O)R^n$ ,  $-NR^nC(O)R^n$ ,  $-NHC(O)NH_2$ ,  $-NR^nC(O)NH_2$ ,  
 $-NR^nC(O)NHR^n$ ,  $-NHC(O)NHR^n$ ,  $-NR^nC(O)N(R^n)_2$ ,  $-NHC(O)N(R^n)_2$ ,  $-CO_2H$ ,  
 $-CO_2R^n$ ,  $-NHCO_2R^n$ ,  $-NR^nCO_2R^n$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NHR^n$ ,  $-N(R^n)_2$ ,  
 $-NR^nS(O)NH_2$  and  $-NR^nS(O)_2NHR^n$ , wherein each  $R^n$  is independently an  
unsubstituted  $C_{1-6}$  alkyl;

HAr is a heteroaryl group selected from the group consisting of pyrazolyl, imidazolyl,  
triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxathiadiazolyl, pyrrolyl,  
thiazolyl, isothiazolyl, benzimidazolyl, benzopyrazolyl and benzotriazolyl, each of  
which is substituted with from one to five  $R^3$  substituents independently selected  
from the group consisting of halogen,  $-OR^f$ ,  $-OC(O)R^f$ ,  $-NR^fR^g$ ,  $-SR^f$ ,  $-R^h$ ,  $-CN$ ,  
 $-NO_2$ ,  $-CO_2R^f$ ,  $-CONR^fR^g$ ,  $-C(O)R^f$ ,  $-OC(O)NR^fR^g$ ,  $-NR^gC(O)R^f$ ,  $-NR^gC(O)_2R^h$ ,  
 $-NR^f-C(O)NR^fR^g$ ,  $-NH-C(NH_2)=NH$ ,  $-NR^hC(NH_2)=NH$ ,  $-NH-C(NH_2)=NR^h$ ,  $-NH-$   
 $C(NHR^h)=NH$ ,  $-S(O)R^h$ ,  $-S(O)_2R^h$ ,  $-NR^fS(O)_2R^h$ ,  $-S(O)_2NR^fR^g$ ,  $-NR^fS(O)_2NR^fR^g$ ,  
 $-N_3$ ,  $-X^3OR^f$ ,  $-X^3OC(O)R^f$ ,  $-X^3NR^fR^g$ ,  $-X^3SR^f$ ,  $-X^3CN$ ,  $-X^3NO_2$ ,  $-X^3CO_2R^f$ ,  
 $-X^3CONR^fR^g$ ,  $-X^3C(O)R^f$ ,  $-X^3OC(O)NR^fR^g$ ,  $-X^3NR^gC(O)R^f$ ,  $-X^3NR^gC(O)_2R^h$ ,  
 $-X^3NR^f-C(O)NR^fR^g$ ,  $-X^3NH-C(NH_2)=NH$ ,  $-X^3NR^hC(NH_2)=NH$ ,  $-X^3NH-$   
 $C(NH_2)=NR^h$ ,  $-X^3NH-C(NHR^h)=NH$ ,  $-X^3S(O)R^h$ ,  $-X^3S(O)_2R^h$ ,  $-X^3NR^fS(O)_2R^h$ ,

$-X^3S(O)_2NR^fR^g$ ,  $-Y$ ,  $-X^3Y$ ,  $-X^3N_3$ ,  $-O-X^3OR^f$ ,  $-O-X^3NR^fR^g$ ,  $-O-X^3CO_2R^f$ ,  
 $-O-X^3CONR^fR^g$ ,  $-NR^g-X^3OR^f$ ,  $-NR^g-X^3NR^fR^g$ ,  $-NR^g-X^3CO_2R^f$ , and  
 $-NR^g-X^3CONR^fR^g$ , wherein  $Y$  is a five or six-membered aryl, heteroaryl or  
heterocyclic ring, optionally substituted with from one to three substituents  
selected from the group consisting of halogen,  $-OR^f$ ,  $-NR^fR^g$ ,  $-R^h$ ,  $-SR^f$ ,  $-CN$ ,  $-$   
 $NO_2$ ,  $-CO_2R^f$ ,  $-CONR^fR^g$ ,  $-C(O)R^f$ ,  $-NR^gC(O)R^f$ ,  $-S(O)R^h$ ,  $-S(O)_2R^h$ ,  $-$   
 $NR^fS(O)_2R^h$ ,  $-S(O)_2NR^fR^g$ ,  $-X^3OR^f$ ,  $-X^3NR^fR^g$ ,  $-X^3NR^fS(O)_2R^h$  and  
 $-X^3S(O)_2NR^fR^g$ , and wherein each  $X^3$  is independently selected from the group  
consisting of  $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene and  $C_{2-4}$  alkynylene and each  $R^f$  and  $R^g$   
is independently selected from hydrogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$   
cycloalkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy-  
 $C_{1-4}$  alkyl, or when attached to the same nitrogen atom can be combined with the  
nitrogen atom to form a five or six-membered ring having from 0 to 2 additional  
heteroatoms as ring members, and each  $R^h$  is independently selected from the  
group consisting of  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$   
alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl, wherein the  
aliphatic portions of  $R^f$ ,  $R^g$  and  $R^h$  is optionally further substituted with from one  
to three members selected from the group consisting of  $-OH$ ,  $-OR^o$ ,  $-OC(O)NHR^o$ ,  
 $-OC(O)N(R^o)_2$ ,  $-SH$ ,  $-SR^o$ ,  $-S(O)R^o$ ,  $-S(O)_2R^o$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^o$ ,  
 $-S(O)_2N(R^o)_2$ ,  $-NHS(O)_2R^o$ ,  $-NR^oS(O)_2R^o$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^o$ ,  $-C(O)N(R^o)_2$ ,  
 $-C(O)R^o$ ,  $-NHC(O)R^o$ ,  $-NR^oC(O)R^o$ ,  $-NHC(O)NH_2$ ,  $-NR^oC(O)NH_2$ ,  
 $-NR^oC(O)NHR^o$ ,  $-NHC(O)NHR^o$ ,  $-NR^oC(O)N(R^o)_2$ ,  $-NHC(O)N(R^o)_2$ ,  $-CO_2H$ ,  
 $-CO_2R^o$ ,  $-NHCO_2R^o$ ,  $-NR^oCO_2R^o$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NHR^o$ ,  $-N(R^o)_2$ ,  
 $-NR^oS(O)NH_2$  and  $-NR^oS(O)_2NHR^o$ , wherein each  $R^o$  is independently an  
unsubstituted  $C_{1-6}$  alkyl;

$L^1$  is a linking group having from one to three main chain atoms selected from the group  
consisting of C, N, O and S and being optionally substituted with from one to  
three substituents selected from the group consisting of halogen, phenyl,  $-OR^i$ ,  
 $-OC(O)R^i$ ,  $-NR^iR^j$ ,  $-SR^i$ ,  $-R^k$ ,  $-CN$ ,  $-NO_2$ ,  $-CO_2R^i$ ,  $-CONR^iR^j$ ,  $-C(O)R^i$ ,  
 $-OC(O)NR^iR^j$ ,  $-NR^jC(O)R^i$ ,  $-NR^jC(O)_2R^k$ ,  $-X^4OR^i$ ,  $-X^4OC(O)R^i$ ,  $-X^4NR^iR^j$ ,  $-$   
 $X^4SR^i$ ,  $-X^4CN$ ,  $-X^4NO_2$ ,  $-X^4CO_2R^i$ ,  $-X^4CONR^iR^j$ ,  $-X^4C(O)R^i$ ,  $-X^4OC(O)NR^iR^j$ ,  $-$   
 $X^4NR^jC(O)R^i$  and  $-X^4NR^jC(O)_2R^k$ , wherein  $X^4$  is selected from the group  
consisting of  $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene and  $C_{2-4}$  alkynylene and each  $R^i$  and  $R^j$   
is independently selected from hydrogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$

cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, and each R<sup>k</sup> is independently selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl; and

with the proviso that the compound is other than CAS Reg. No. 492422-98-7, 1-[[4-bromo-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-(5-chloro-2-methylphenyl)-piperazine; CAS Reg. No. 351986-92-0, 1-[[4-chloro-5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-(4-fluorophenyl)-piperazine; CAS Reg. No. 356039-23-1, 1-[(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)acetyl]-4-(4-fluorophenyl)-piperazine; 1-(2-{4-nitro-3,5-dimethyl-1H-pyrazol-1-yl}propanoyl)-4-phenylpiperazine; 2-(2,4-Dinitro-imidazol-1-yl)-1-[4-(4-fluorophenyl)-piperazin-1-yl]-ethanone; 2-(2,4-Dinitro-imidazol-1-yl)-1-(4-phenyl-piperazin-1-yl)-ethanone; 2-(4-Nitro-imidazol-1-yl)-1-(4-phenyl-piperazin-1-yl)-ethanone; and CAS Reg. No. 492992-15-1, 3-[3-Fluoro-4-[4-[(1-pyrazolyl)acetyl]piperazine-1-yl]phenyl]-5-[(isoxazol-3-yl)amino]methylisoxazole.

2. A compound of claim 1, wherein Ar<sup>1</sup> is selected from the group consisting of:

- (i) phenyl, substituted with from 1 to 5 R<sup>2</sup> groups;
- (ii) pyridinyl, substituted with from 1 to 4 R<sup>2</sup> groups; and
- (iii) pyrimidinyl, substituted with from 1 to 3 R<sup>2</sup> groups;
- (iv) pyrazinyl, substituted with from 1 to 3 R<sup>2</sup> groups; and
- (v) pyridazinyl, substituted with from 1 to 3 R<sup>2</sup> groups;

wherein each R<sup>2</sup> is a member independently selected from the group consisting of halogen, -OR<sup>c</sup>, -OC(O)R<sup>c</sup>, -NR<sup>c</sup>R<sup>d</sup>, -SR<sup>c</sup>, -R<sup>e</sup>, -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R<sup>c</sup>, -CONR<sup>c</sup>R<sup>d</sup>, -C(O)R<sup>c</sup>, -OC(O)NR<sup>c</sup>R<sup>d</sup>, -NR<sup>d</sup>C(O)R<sup>c</sup>, -NR<sup>d</sup>C(O)<sub>2</sub>R<sup>c</sup>, -NR<sup>c</sup>-C(O)NR<sup>c</sup>R<sup>d</sup>, -S(O)R<sup>e</sup>, -S(O)<sub>2</sub>R<sup>e</sup>, -NR<sup>c</sup>S(O)<sub>2</sub>R<sup>e</sup>, -S(O)<sub>2</sub>NR<sup>c</sup>R<sup>d</sup> and -N<sub>3</sub>.

3. A compound of claim 1, wherein Ar<sup>1</sup> is selected from the group consisting of:

- (i) phenyl, substituted with from 1 to 5 R<sup>2</sup> groups;
- (ii) pyridinyl, substituted with from 1 to 4 R<sup>2</sup> groups; and
- (iii) pyrimidinyl, substituted with from 1 to 3 R<sup>2</sup> groups;

6 (iv) pyrazinyl, substituted with from 1 to 3 R<sup>2</sup> groups; and  
 7 (v) pyridazinyl, substituted with from 1 to 3 R<sup>2</sup> groups;  
 8 wherein each R<sup>2</sup> is a member independently selected from the group  
 9 consisting of halogen, -X<sup>2</sup>OR<sup>c</sup>, -O-X<sup>2</sup>OR<sup>c</sup>, -X<sup>2</sup>OC(O)R<sup>c</sup>, -X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>, -O-X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>SR<sup>c</sup>, -  
 10 X<sup>2</sup>CN, -X<sup>2</sup>NO<sub>2</sub>, -X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, -O-X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, -X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>, -O-X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>C(O)R<sup>c</sup>,  
 11 -X<sup>2</sup>OC(O)NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>NR<sup>d</sup>C(O)R<sup>c</sup>, -X<sup>2</sup>NR<sup>d</sup>C(O)<sub>2</sub>R<sup>c</sup>, -X<sup>2</sup>NR<sup>c</sup>C(O)NR<sup>c</sup>R<sup>d</sup>,  
 12 -X<sup>2</sup>NH-C(NH<sub>2</sub>)=NH, -X<sup>2</sup>NR<sup>c</sup>C(NH<sub>2</sub>)=NH, -X<sup>2</sup>NH-C(NH<sub>2</sub>)=NR<sup>c</sup>, -X<sup>2</sup>NH-C(NHR<sup>c</sup>)=NH, -  
 13 X<sup>2</sup>S(O)R<sup>c</sup>, -X<sup>2</sup>S(O)<sub>2</sub>R<sup>c</sup>, -X<sup>2</sup>NR<sup>c</sup>S(O)<sub>2</sub>R<sup>c</sup>, -X<sup>2</sup>S(O)<sub>2</sub>NR<sup>c</sup>R<sup>d</sup> and -X<sup>2</sup>N<sub>3</sub>.

1 4. A compound of claim 1, wherein Ar<sup>1</sup> is phenyl substituted with from 1  
 2 to 3 R<sup>2</sup> groups.

1 5. A compound of claim 4, wherein L<sup>1</sup> is -CH<sub>2</sub>- and is optionally  
 2 substituted with phenyl, -R<sup>k</sup>, -X<sup>4</sup>OR<sup>i</sup>, -X<sup>4</sup>OC(O)R<sup>i</sup>, -X<sup>4</sup>NR<sup>i</sup>R<sup>j</sup>, -X<sup>4</sup>SR<sup>i</sup>, -X<sup>4</sup>CN or -X<sup>4</sup>NO<sub>2</sub>.

1 6. A compound of claim 5, wherein HAr is a member selected from the  
 2 group consisting of pyrazolyl and triazolyl, which is optionally substituted with from one to  
 3 three R<sup>3</sup> groups independently selected from the group consisting of halogen, -OR<sup>f</sup>,  
 4 -OC(O)R<sup>f</sup>, -NR<sup>f</sup>R<sup>g</sup>, -SR<sup>f</sup>, -R<sup>h</sup>, -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R<sup>f</sup>, -CONR<sup>f</sup>R<sup>g</sup>, -C(O)R<sup>f</sup>, -OC(O)NR<sup>f</sup>R<sup>g</sup>, -  
 5 NR<sup>g</sup>C(O)R<sup>f</sup>, -NR<sup>g</sup>C(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>-C(O)NR<sup>f</sup>R<sup>g</sup>, -NH-C(NH<sub>2</sub>)=NH, -NR<sup>h</sup>C(NH<sub>2</sub>)=NH, -NH-  
 6 C(NH<sub>2</sub>)=NR<sup>h</sup>, -NH-C(NHR<sup>h</sup>)=NH, -S(O)R<sup>h</sup>, -S(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, -S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -  
 7 NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -N<sub>3</sub>, -X<sup>3</sup>OR<sup>f</sup>, -X<sup>3</sup>OC(O)R<sup>f</sup>, -X<sup>3</sup>NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>SR<sup>f</sup>, -X<sup>3</sup>CN, -  
 8 X<sup>3</sup>NO<sub>2</sub>, -X<sup>3</sup>CO<sub>2</sub>R<sup>f</sup>, -X<sup>3</sup>CONR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>C(O)R<sup>f</sup>, -X<sup>3</sup>OC(O)NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>NR<sup>g</sup>C(O)R<sup>f</sup>, -  
 9 X<sup>3</sup>NR<sup>g</sup>C(O)<sub>2</sub>R<sup>h</sup>, -X<sup>3</sup>NR<sup>f</sup>-C(O)NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>NH-C(NH<sub>2</sub>)=NH, -X<sup>3</sup>NR<sup>h</sup>C(NH<sub>2</sub>)=NH, -X<sup>3</sup>NH-  
 10 C(NH<sub>2</sub>)=NR<sup>h</sup>, -X<sup>3</sup>NH-C(NHR<sup>h</sup>)=NH, -X<sup>3</sup>S(O)R<sup>h</sup>, -X<sup>3</sup>S(O)<sub>2</sub>R<sup>h</sup>, -X<sup>3</sup>NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>,  
 11 -X<sup>3</sup>S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -Y, -X<sup>3</sup>Y and -X<sup>3</sup>N<sub>3</sub> wherein Y is a five or six-membered aryl, heteroaryl or  
 12 heterocyclic ring, optionally substituted with from one to three substituents selected from the  
 13 group consisting of halogen, -OR<sup>f</sup>, -NR<sup>f</sup>R<sup>g</sup>, -R<sup>h</sup>, -SR<sup>f</sup>, -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R<sup>f</sup>, -CONR<sup>f</sup>R<sup>g</sup>,  
 14 -C(O)R<sup>f</sup>, -NR<sup>g</sup>C(O)R<sup>f</sup>, -S(O)R<sup>h</sup>, -S(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, -S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>OR<sup>f</sup>, -X<sup>3</sup>NR<sup>f</sup>R<sup>g</sup>, -  
 15 X<sup>3</sup>NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup> and -X<sup>3</sup>S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, and wherein each X<sup>3</sup> is independently selected from the  
 16 group consisting of C<sub>1-4</sub> alkylene, C<sub>2-4</sub> alkenylene and C<sub>2-4</sub> alkynylene and each R<sup>f</sup> and R<sup>g</sup> is  
 17 independently selected from hydrogen, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl,  
 18 C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, or when attached to the  
 19 same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered  
 20 ring having from 0 to 2 additional heteroatoms as ring members, and each R<sup>h</sup> is

21 independently selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl,  
 22 C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, wherein the  
 23 aliphatic portions of R<sup>f</sup>, R<sup>g</sup> and R<sup>h</sup> are optionally further substituted with from one to three  
 24 members selected from the group consisting of -OH, -OR<sup>o</sup>, -OC(O)NHR<sup>o</sup>, -OC(O)N(R<sup>o</sup>)<sub>2</sub>,  
 25 -SH, -SR<sup>o</sup>, -S(O)R<sup>o</sup>, -S(O)<sub>2</sub>R<sup>o</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>o</sup>, -S(O)<sub>2</sub>N(R<sup>o</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>o</sup>,  
 26 -NR<sup>o</sup>S(O)<sub>2</sub>R<sup>o</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>o</sup>, -C(O)N(R<sup>o</sup>)<sub>2</sub>, -C(O)R<sup>o</sup>, -NHC(O)R<sup>o</sup>, -NR<sup>o</sup>C(O)R<sup>o</sup>,  
 27 -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>,  
 28 -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>, -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>,  
 29 -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>, wherein R<sup>o</sup> is unsubstituted C<sub>1-6</sub> alkyl.

1                   7.       A compound of claim 6, wherein n is 1, m is 0-2, Ar<sup>1</sup> is phenyl  
 2 substituted with from one to three R<sup>2</sup> groups, HAr is pyrazolyl which is substituted with three  
 3 R<sup>3</sup> groups and L<sup>1</sup> is -CH<sub>2</sub>-.

1                   8.       A compound in accordance with claim 7, wherein said Ar<sup>1</sup> is selected  
 2 from the substituted phenyl moieties provided in Figures 1A and 1B.


1                   9.       A compound in accordance with claim 7, wherein said HAr is selected  
 2 from the substituted pyrazole groups provided in Figures 2A, 2B, 2C, 2D, 2E, 2F and 3.

1                   10.      A compound of claim 8, wherein one of said R<sup>3</sup> groups is selected  
 2 from the group consisting of -Y and -X<sup>3</sup>-Y, wherein Y is selected from the group consisting  
 3 of phenyl, thienyl, furanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridizynyl, pyrazolyl, imidazolyl,  
 4 thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl and oxadiazolyl, which is  
 5 optionally substituted with from one to three substituents independently selected from the  
 6 group consisting of halogen, -OR<sup>f</sup>, -NR<sup>f</sup>R<sup>g</sup>, -COR<sup>f</sup>, -CO<sub>2</sub>R<sup>f</sup>, -CONR<sup>f</sup>R<sup>g</sup>, -NO<sub>2</sub>, -R<sup>h</sup>, -CN,  
 7 -X<sup>3</sup>-OR<sup>f</sup>, -X<sup>3</sup>-NR<sup>f</sup>R<sup>g</sup> and -X<sup>3</sup>-NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, wherein R<sup>f</sup> and R<sup>g</sup> are each independently selected  
 8 from the group consisting of H, C<sub>1-8</sub> alkyl, C<sub>3-6</sub> cycloalkyl and C<sub>1-8</sub> haloalkyl, and each R<sup>h</sup> is  
 9 independently selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>3-6</sub> cycloalkyl and C<sub>1-8</sub>  
 10 haloalkyl.

1                   11.      A compound of claim 10, wherein Y is selected from the group  
 2 consisting of phenyl and thienyl, each of which is optionally substituted with from one to  
 3 three substituents independently selected from the group consisting of halogen, -OR<sup>f</sup>,  
 4 -NR<sup>f</sup>R<sup>g</sup>, -COR<sup>f</sup>, -CO<sub>2</sub>R<sup>f</sup>, -CONR<sup>f</sup>R<sup>g</sup>, -NO<sub>2</sub>, -R<sup>h</sup>, -CN, -X<sup>3</sup>-OR<sup>f</sup>, -X<sup>3</sup>-NR<sup>f</sup>R<sup>g</sup> and  
 5 -X<sup>3</sup>-NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, wherein R<sup>f</sup> and R<sup>g</sup> are each independently selected from the group

consisting of H, C<sub>1-8</sub> alkyl, C<sub>3-6</sub> cycloalkyl and C<sub>1-8</sub> haloalkyl, and each R<sup>h</sup> is independently selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>3-6</sub> cycloalkyl and C<sub>1-8</sub> haloalkyl.

12. A compound of claim 1, having the formula:



or a pharmaceutically acceptable salt or N-oxide thereof, wherein each of R<sup>1a</sup>, R<sup>1b</sup>, R<sup>1c</sup>, R<sup>1d</sup>, R<sup>1e</sup>, R<sup>1f</sup>, R<sup>1g</sup> and R<sup>1h</sup> represents a member independently selected from the group consisting of H, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, -COR<sup>a</sup>, -CO<sub>2</sub>R<sup>a</sup>, -CONR<sup>a</sup>R<sup>b</sup>, -NR<sup>a</sup>COR<sup>b</sup>, -SO<sub>2</sub>R<sup>a</sup>, -X<sup>1</sup>COR<sup>a</sup>, -X<sup>1</sup>CO<sub>2</sub>R<sup>a</sup>, -X<sup>1</sup>CONR<sup>a</sup>R<sup>b</sup>, -X<sup>1</sup>NR<sup>a</sup>COR<sup>b</sup>, -X<sup>1</sup>SO<sub>2</sub>R<sup>a</sup>, -X<sup>1</sup>SO<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, -X<sup>1</sup>NR<sup>a</sup>R<sup>b</sup>, -X<sup>1</sup>OR<sup>a</sup>, wherein X<sup>1</sup> is a member selected from the group consisting of C<sub>1-4</sub> alkylene, C<sub>2-4</sub> alkenylene and C<sub>2-4</sub> alkynylene and each R<sup>a</sup> and R<sup>b</sup> is independently selected from the group consisting of hydrogen, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl and aryl-C<sub>1-4</sub>alkyl, and wherein the aliphatic portions of each of said R<sup>1</sup> substituents is optionally substituted with from one to three members selected from the group consisting of -OH, -OR<sup>m</sup>, -OC(O)NHR<sup>m</sup>, -OC(O)N(R<sup>m</sup>)<sub>2</sub>, -SH, -SR<sup>m</sup>, -S(O)R<sup>m</sup>, -S(O)<sub>2</sub>R<sup>m</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>m</sup>, -S(O)<sub>2</sub>N(R<sup>m</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>m</sup>, -NR<sup>m</sup>S(O)<sub>2</sub>R<sup>m</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>m</sup>, -C(O)N(R<sup>m</sup>)<sub>2</sub>, -C(O)R<sup>m</sup>, -NHC(O)R<sup>m</sup>, -NR<sup>m</sup>C(O)R<sup>m</sup>, -NHC(O)NH<sub>2</sub>, -NR<sup>m</sup>C(O)NH<sub>2</sub>, -NR<sup>m</sup>C(O)NHR<sup>m</sup>, -NHC(O)NHR<sup>m</sup>, -NR<sup>m</sup>C(O)N(R<sup>m</sup>)<sub>2</sub>, -NHC(O)N(R<sup>m</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>m</sup>, -NHCO<sub>2</sub>R<sup>m</sup>, -NR<sup>m</sup>CO<sub>2</sub>R<sup>m</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>m</sup>, -N(R<sup>m</sup>)<sub>2</sub>, -NR<sup>m</sup>S(O)NH<sub>2</sub> and -NR<sup>m</sup>S(O)<sub>2</sub>NHR<sup>m</sup>, wherein each R<sup>m</sup> is independently an unsubstituted C<sub>1-6</sub> alkyl; Ar<sup>1</sup> is phenyl, substituted with from 1 to 5 R<sup>2</sup> groups; and HAr is pyrazolyl, substituted with from 1 to 3 R<sup>3</sup> groups.

13. A compound of claim 12, wherein L<sup>1</sup> is -CH<sub>2</sub>-.


14. A compound of claim 13, wherein said HAr is selected from the substituted pyrazolyl moieties provided in Figures 2A, 2B, 2C, 2D, 2E, 2F and 3.

15. A compound of claim 14, wherein Ar<sup>1</sup> is phenyl substituted with from one to three independently selected R<sup>2</sup> substituents.

16. A compound of claim 15, wherein said Ar<sup>1</sup> is selected from the substituted phenyl moieties provided in Figures 1A and 1B.

17. A compound of claim 16, wherein no more than two of R<sup>1a</sup> through R<sup>1h</sup> are other than H.

18. A compound of claim 1, having the formula:



wherein the subscript m is an integer of from 0 to 2;

each R<sup>1</sup> is a member selected from the group consisting of -CO<sub>2</sub>H, C<sub>1-4</sub> alkyl and C<sub>1-4</sub>

haloalkyl, wherein the aliphatic portions are optionally substituted with -OH,

-OR<sup>m</sup>, -OC(O)NHR<sup>m</sup>, -OC(O)N(R<sup>m</sup>)<sub>2</sub>, -SH, -SR<sup>m</sup>, -S(O)R<sup>m</sup>, -S(O)<sub>2</sub>R<sup>m</sup>, -SO<sub>2</sub>NH<sub>2</sub>,

-S(O)<sub>2</sub>NHR<sup>m</sup>, -S(O)<sub>2</sub>N(R<sup>m</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>m</sup>, -NR<sup>m</sup>S(O)<sub>2</sub>R<sup>m</sup>, -C(O)NH<sub>2</sub>,

-C(O)NHR<sup>m</sup>, -C(O)N(R<sup>m</sup>)<sub>2</sub>, -C(O)R<sup>m</sup>, -NHC(O)R<sup>m</sup>, -NR<sup>m</sup>C(O)R<sup>m</sup>, -NHC(O)NH<sub>2</sub>,

-NR<sup>m</sup>C(O)NH<sub>2</sub>, -NR<sup>m</sup>C(O)NHR<sup>m</sup>, -NHC(O)NHR<sup>m</sup>, -NR<sup>m</sup>C(O)N(R<sup>m</sup>)<sub>2</sub>,

-NHC(O)N(R<sup>m</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>m</sup>, -NHCO<sub>2</sub>R<sup>m</sup>, -NR<sup>m</sup>CO<sub>2</sub>R<sup>m</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>,

-NHR<sup>m</sup>, -N(R<sup>m</sup>)<sub>2</sub>, -NR<sup>m</sup>S(O)NH<sub>2</sub> and -NR<sup>m</sup>S(O)<sub>2</sub>NHR<sup>m</sup>, wherein each R<sup>m</sup> is

independently an unsubstituted C<sub>1-6</sub> alkyl;

R<sup>2a</sup>, R<sup>2b</sup>, R<sup>2c</sup>, R<sup>2d</sup> and R<sup>2e</sup> are each members independently selected from the group

consisting of hydrogen, halogen, -OR<sup>c</sup>, -OC(O)R<sup>c</sup>, -NR<sup>c</sup>R<sup>d</sup>, -SR<sup>c</sup>, -R<sup>e</sup>, -CN, -NO<sub>2</sub>,

-CO<sub>2</sub>R<sup>c</sup>, -CONR<sup>c</sup>R<sup>d</sup>, -C(O)R<sup>c</sup>, -OC(O)NR<sup>c</sup>R<sup>d</sup>, -NR<sup>d</sup>C(O)R<sup>c</sup>, -NR<sup>d</sup>C(O)<sub>2</sub>R<sup>e</sup>, -NR<sup>c</sup>-

C(O)NR<sup>c</sup>R<sup>d</sup>, -NH-C(NH<sub>2</sub>)=NH, -NR<sup>c</sup>C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR<sup>e</sup>, -NH-

C(NHR<sup>e</sup>)=NH, -S(O)R<sup>e</sup>, -S(O)<sub>2</sub>R<sup>e</sup>, -NR<sup>c</sup>S(O)<sub>2</sub>R<sup>e</sup>, -S(O)<sub>2</sub>NR<sup>c</sup>R<sup>d</sup>, -N<sub>3</sub>, -X<sup>2</sup>OR<sup>c</sup>,

-O-X<sup>2</sup>OR<sup>c</sup>, -X<sup>2</sup>OC(O)R<sup>c</sup>, -X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>, -O-X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>SR<sup>c</sup>, -X<sup>2</sup>CN, -X<sup>2</sup>NO<sub>2</sub>, -

X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, -O-X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, -X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>, -O-X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>C(O)R<sup>c</sup>,

-X<sup>2</sup>OC(O)NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>NR<sup>d</sup>C(O)R<sup>c</sup>, -X<sup>2</sup>NR<sup>d</sup>C(O)<sub>2</sub>R<sup>e</sup>, -X<sup>2</sup>NR<sup>c</sup>C(O)NR<sup>c</sup>R<sup>d</sup>,

-X<sup>2</sup>NH-C(NH<sub>2</sub>)=NH, -X<sup>2</sup>NR<sup>c</sup>C(NH<sub>2</sub>)=NH, -X<sup>2</sup>NH-C(NH<sub>2</sub>)=NR<sup>e</sup>, -X<sup>2</sup>NH-

C(NHR<sup>e</sup>)=NH, -X<sup>2</sup>S(O)R<sup>e</sup>, -X<sup>2</sup>S(O)<sub>2</sub>R<sup>e</sup>, -X<sup>2</sup>NR<sup>c</sup>S(O)<sub>2</sub>R<sup>e</sup>, -X<sup>2</sup>S(O)<sub>2</sub>NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>N<sub>3</sub>,

-NR<sup>d</sup>-X<sup>2</sup>OR<sup>c</sup>, -NR<sup>d</sup>-X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>, -NR<sup>d</sup>-X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, and -NR<sup>d</sup>-X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>, wherein

X<sup>2</sup> is a member selected from the group consisting of C<sub>1-4</sub> alkylene, C<sub>2-4</sub>

alkenylene and C<sub>2-4</sub> alkynylene and each R<sup>c</sup> and R<sup>d</sup> is independently selected from

hydrogen, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl,



heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, or optionally R<sup>c</sup> and R<sup>d</sup> when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members; and each R<sup>e</sup> is independently selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, and each of R<sup>c</sup>, R<sup>d</sup> and R<sup>e</sup> is optionally further substituted with from one to three members selected from the group consisting of -OH, -OR<sup>n</sup>, -OC(O)NHR<sup>n</sup>, -OC(O)N(R<sup>n</sup>)<sub>2</sub>, -SH, -SR<sup>n</sup>, -S(O)R<sup>n</sup>, -S(O)<sub>2</sub>R<sup>n</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>n</sup>, -S(O)<sub>2</sub>N(R<sup>n</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>n</sup>, -NR<sup>n</sup>S(O)<sub>2</sub>R<sup>n</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>n</sup>, -C(O)N(R<sup>n</sup>)<sub>2</sub>, -C(O)R<sup>n</sup>, -NHC(O)R<sup>n</sup>, -NR<sup>n</sup>C(O)R<sup>n</sup>, -NHC(O)NH<sub>2</sub>, -NR<sup>n</sup>C(O)NH<sub>2</sub>, -NR<sup>n</sup>C(O)NHR<sup>n</sup>, -NHC(O)NHR<sup>n</sup>, -NR<sup>n</sup>C(O)N(R<sup>n</sup>)<sub>2</sub>, -NHC(O)N(R<sup>n</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>n</sup>, -NHCO<sub>2</sub>R<sup>n</sup>, -NR<sup>n</sup>CO<sub>2</sub>R<sup>n</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>n</sup>, -N(R<sup>n</sup>)<sub>2</sub>, -NR<sup>n</sup>S(O)NH<sub>2</sub> and -NR<sup>n</sup>S(O)<sub>2</sub>NHR<sup>n</sup>, wherein each R<sup>n</sup> is independently an unsubstituted C<sub>1-6</sub> alkyl, such that at least one of R<sup>2a</sup>, R<sup>2b</sup>, R<sup>2c</sup>, R<sup>2d</sup> and R<sup>2e</sup> is other than H;

R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> are each members independently selected from the group consisting of hydrogen, halogen, -OR<sup>f</sup>, -OC(O)R<sup>f</sup>, -NR<sup>f</sup>R<sup>g</sup>, -SR<sup>f</sup>, -R<sup>h</sup>, -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R<sup>f</sup>, -CONR<sup>f</sup>R<sup>g</sup>, -C(O)R<sup>f</sup>, -OC(O)NR<sup>f</sup>R<sup>g</sup>, -NR<sup>g</sup>C(O)R<sup>f</sup>, -NR<sup>g</sup>C(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>-C(O)NR<sup>f</sup>R<sup>g</sup>, -NH-C(NH<sub>2</sub>)=NH, -NR<sup>h</sup>C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR<sup>h</sup>, -NH-C(NHR<sup>h</sup>)=NH, -S(O)R<sup>h</sup>, -S(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, -S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -NR<sup>f</sup>S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -N<sub>3</sub>, -X<sup>3</sup>OR<sup>f</sup>, -X<sup>3</sup>OC(O)R<sup>f</sup>, -X<sup>3</sup>NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>SR<sup>f</sup>, -X<sup>3</sup>CN, -X<sup>3</sup>NO<sub>2</sub>, -X<sup>3</sup>CO<sub>2</sub>R<sup>f</sup>, -X<sup>3</sup>CONR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>C(O)R<sup>f</sup>, -X<sup>3</sup>OC(O)NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>NR<sup>g</sup>C(O)R<sup>f</sup>, -X<sup>3</sup>NR<sup>g</sup>C(O)<sub>2</sub>R<sup>h</sup>, -X<sup>3</sup>NR<sup>f</sup>-C(O)NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>NH-C(NH<sub>2</sub>)=NH, -X<sup>3</sup>NR<sup>h</sup>C(NH<sub>2</sub>)=NH, -X<sup>3</sup>NH-C(NH<sub>2</sub>)=NR<sup>h</sup>, -X<sup>3</sup>NH-C(NHR<sup>h</sup>)=NH, -X<sup>3</sup>S(O)R<sup>h</sup>, -X<sup>3</sup>S(O)<sub>2</sub>R<sup>h</sup>, -X<sup>3</sup>NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, -X<sup>3</sup>S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -Y, -X<sup>3</sup>Y, -X<sup>3</sup>N<sub>3</sub>, -O-X<sup>3</sup>OR<sup>f</sup>, -O-X<sup>3</sup>NR<sup>f</sup>R<sup>g</sup>, -O-X<sup>3</sup>CO<sub>2</sub>R<sup>f</sup>, -O-X<sup>3</sup>CONR<sup>f</sup>R<sup>g</sup>, -NR<sup>g</sup>-X<sup>3</sup>OR<sup>f</sup>, -NR<sup>g</sup>-X<sup>3</sup>NR<sup>f</sup>R<sup>g</sup>, -NR<sup>g</sup>-X<sup>3</sup>CO<sub>2</sub>R<sup>f</sup>, and -NR<sup>g</sup>-X<sup>3</sup>CONR<sup>f</sup>R<sup>g</sup>, wherein Y is a five or six-membered aryl, heteroaryl or heterocyclic ring, optionally substituted with from one to three substituents selected from the group consisting of halogen, -OR<sup>f</sup>, -NR<sup>f</sup>R<sup>g</sup>, -R<sup>h</sup>, -SR<sup>f</sup>, -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R<sup>f</sup>, -CONR<sup>f</sup>R<sup>g</sup>, -C(O)R<sup>f</sup>, -NR<sup>g</sup>C(O)R<sup>f</sup>, -S(O)R<sup>h</sup>, -S(O)<sub>2</sub>R<sup>h</sup>, -NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup>, -S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>OR<sup>f</sup>, -X<sup>3</sup>NR<sup>f</sup>R<sup>g</sup>, -X<sup>3</sup>NR<sup>f</sup>S(O)<sub>2</sub>R<sup>h</sup> and -X<sup>3</sup>S(O)<sub>2</sub>NR<sup>f</sup>R<sup>g</sup>, and wherein each X<sup>3</sup> is independently selected from the group consisting of C<sub>1-4</sub> alkylene, C<sub>2-4</sub> alkenylene and C<sub>2-4</sub> alkynylene and each R<sup>f</sup> and R<sup>g</sup> is independently selected from hydrogen, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub>

cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members, and each R<sup>h</sup> is independently selected from the group consisting of C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl, aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl, wherein the aliphatic portions of R<sup>f</sup>, R<sup>g</sup> and R<sup>h</sup> is optionally further substituted with from one to three members selected from the group consisting of -OH, -OR<sup>o</sup>, -OC(O)NHR<sup>o</sup>, -OC(O)N(R<sup>o</sup>)<sub>2</sub>, -SH, -SR<sup>o</sup>, -S(O)R<sup>o</sup>, -S(O)<sub>2</sub>R<sup>o</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>o</sup>, -S(O)<sub>2</sub>N(R<sup>o</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>S(O)<sub>2</sub>R<sup>o</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>o</sup>, -C(O)N(R<sup>o</sup>)<sub>2</sub>, -C(O)R<sup>o</sup>, -NHC(O)R<sup>o</sup>, -NR<sup>o</sup>C(O)R<sup>o</sup>, -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>, -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>, -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>, -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>, wherein each R<sup>o</sup> is independently an unsubstituted C<sub>1-6</sub> alkyl, such that at least one of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is other than H.

**19.** A compound of claim 18, wherein at least one of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is selected from the group consisting of -Y and -X<sup>3</sup>-Y.

**20.** A compound of claim 18, wherein m is 0 or 1; at least one of R<sup>2a</sup> and R<sup>2c</sup> is hydrogen.

**21.** A compound of claim 18, wherein R<sup>3b</sup> is halogen.

**22.** A compound of claim 21, wherein R<sup>1</sup>, when present, is selected from the group consisting of -CO<sub>2</sub>H or C<sub>1-4</sub> alkyl, optionally substituted with -OH, -OR<sup>m</sup>, -S(O)<sub>2</sub>R<sup>m</sup>, -CO<sub>2</sub>H and -CO<sub>2</sub>R<sup>m</sup>.

**23.** A compound of claim 20, wherein at least one of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is selected from the group consisting of halogen, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> haloalkyl, wherein the aliphatic portions are optionally substituted with from one to three members selected from the group consisting of -OH, -OR<sup>o</sup>, -OC(O)NHR<sup>o</sup>, -OC(O)N(R<sup>o</sup>)<sub>2</sub>, -SH, -SR<sup>o</sup>, -S(O)R<sup>o</sup>, -S(O)<sub>2</sub>R<sup>o</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>o</sup>, -S(O)<sub>2</sub>N(R<sup>o</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>S(O)<sub>2</sub>R<sup>o</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>o</sup>, -C(O)N(R<sup>o</sup>)<sub>2</sub>, -C(O)R<sup>o</sup>, -NHC(O)R<sup>o</sup>, -NR<sup>o</sup>C(O)R<sup>o</sup>, -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>, -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>,

8 -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>, -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and  
9 -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>, wherein each R<sup>o</sup> is independently an unsubstituted C<sub>1-6</sub> alkyl.

1                    24.     A compound of claim 23, wherein R<sup>2d</sup> is hydrogen and at least two of  
2 R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> are selected from the group consisting of halogen, C<sub>1-4</sub> alkyl and C<sub>1-4</sub>  
3 haloalkyl, wherein the aliphatic portions are optionally substituted with from one to three  
4 members selected from the group consisting of -OH, -OR<sup>o</sup>, -OC(O)NHR<sup>o</sup>, -OC(O)N(R<sup>o</sup>)<sub>2</sub>,  
5 -SH, -SR<sup>o</sup>, -S(O)R<sup>o</sup>, -S(O)<sub>2</sub>R<sup>o</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>o</sup>, -S(O)<sub>2</sub>N(R<sup>o</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>o</sup>,  
6 -NR<sup>o</sup>S(O)<sub>2</sub>R<sup>o</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>o</sup>, -C(O)N(R<sup>o</sup>)<sub>2</sub>, -C(O)R<sup>o</sup>, -NHC(O)R<sup>o</sup>, -NR<sup>o</sup>C(O)R<sup>o</sup>,  
7 -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>,  
8 -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>, -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>,  
9 -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>, wherein each R<sup>o</sup> is independently an  
10 unsubstituted C<sub>1-6</sub> alkyl.

1                    25.     A compound of claim 24, wherein R<sup>2c</sup> is selected from the group  
2 consisting of F, Cl, Br, CN, NO<sub>2</sub>, CO<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>3</sub> and S(O)<sub>2</sub>CH<sub>3</sub>, and each of R<sup>3a</sup>, R<sup>3b</sup> and  
3 R<sup>3c</sup> is other than hydrogen.

1                    26.     A compound of claim 18, wherein m is 0 or 1; R<sup>2a</sup> and R<sup>2e</sup> are each  
2 hydrogen.


1                    27.     A compound of claim 26, wherein at least one of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is  
2 selected from the group consisting of halogen, C<sub>1-4</sub> alkyl and C<sub>1-4</sub> haloalkyl, wherein the  
3 aliphatic portions are optionally substituted with from one to three members selected from the  
4 group consisting of -OH, -OR<sup>o</sup>, -OC(O)NHR<sup>o</sup>, -OC(O)N(R<sup>o</sup>)<sub>2</sub>, -SH, -SR<sup>o</sup>, -S(O)R<sup>o</sup>, -S(O)<sub>2</sub>R<sup>o</sup>,  
5 -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>o</sup>, -S(O)<sub>2</sub>N(R<sup>o</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>S(O)<sub>2</sub>R<sup>o</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>o</sup>,  
6 -C(O)N(R<sup>o</sup>)<sub>2</sub>, -C(O)R<sup>o</sup>, -NHC(O)R<sup>o</sup>, -NR<sup>o</sup>C(O)R<sup>o</sup>, -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>,  
7 -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>, -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>,  
8 -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>, -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and  
9 -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>, wherein each R<sup>o</sup> is independently an unsubstituted C<sub>1-6</sub> alkyl.

1                    28.     A compound of claim 27, wherein each of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is other  
2 than hydrogen.

1                    29.     A compound of claim 28, wherein R<sup>2c</sup> is selected from the group  
2 consisting of F, Cl, Br, CN, NO<sub>2</sub>, CO<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>3</sub> and S(O)<sub>2</sub>CH<sub>3</sub>.

30. A compound of claim 18, wherein m is 0 or 1; R<sup>2b</sup> and R<sup>2e</sup> are each hydrogen.

31. A compound of claim 18, having a formula selected from the group consisting of:



32. A compound of claim 31, wherein R<sup>3c</sup> and R<sup>3a</sup> are each independently selected from the group consisting of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl and C<sub>3-6</sub> cycloalkyl; and R<sup>3b</sup> is halogen.

33. A compound of claim 31, wherein R<sup>3c</sup> and R<sup>3a</sup> are each independently selected from the group consisting of halogen, -NR<sup>f</sup>R<sup>g</sup>, -SR<sup>f</sup>, -CO<sub>2</sub>R<sup>f</sup>, -Y and -R<sup>h</sup>, wherein R<sup>h</sup> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl and C<sub>3-6</sub> cycloalkyl, wherein the aliphatic portions are optionally further substituted with from one to three members selected from the group consisting of -OH, -OR<sup>o</sup>, -OC(O)NHR<sup>o</sup>, -OC(O)N(R<sup>o</sup>)<sub>2</sub>, -SH, -SR<sup>o</sup>, -S(O)R<sup>o</sup>, -S(O)<sub>2</sub>R<sup>o</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>o</sup>, -S(O)<sub>2</sub>N(R<sup>o</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>S(O)<sub>2</sub>R<sup>o</sup>, -C(O)NH<sub>2</sub>, -C(O)NHR<sup>o</sup>, -C(O)N(R<sup>o</sup>)<sub>2</sub>, -C(O)R<sup>o</sup>, -NHC(O)R<sup>o</sup>, -NR<sup>o</sup>C(O)R<sup>o</sup>, -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>, -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>, -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>, -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>.


34. A compound of claim 33, wherein R<sup>3b</sup> is halogen.

35. A compound of claim 31, wherein m is 0.

36. A compound of claim 31, wherein m is 1 or 2, and each R<sup>1</sup> is independently selected from the group consisting of -CO<sub>2</sub>H and C<sub>1-4</sub> alkyl, wherein the alkyl portion is optionally substituted with -OH, -OR<sup>m</sup>, -S(O)<sub>2</sub>R<sup>m</sup>, -CO<sub>2</sub>H and -CO<sub>2</sub>R<sup>m</sup>.


37. A compound of claim 31, wherein  $R^{2b}$  is selected from the group consisting of  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^e$ ,  $-OR^c$ ,  $-NR^cR^d$ , and  $-NR^cSO_2R^d$ .

38. A compound of claim 18, having the formula:




wherein  $R^{2c}$  is halogen, cyano or nitro;  $R^{2b}$  is selected from  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^e$ ,  $-OR^c$ ,  $-NR^cR^d$ ,  $-NR^cS(O)_2R^e$  and  $-NR^dC(O)R^c$ ;  $R^{3a}$  is selected from the group consisting of  $NH_2$ ,  $CF_3$ ,  $SCH_3$  and  $Y$ ;  $R^{3b}$  is chloro or bromo; and  $R^{3c}$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl and  $C_{3-6}$  cycloalkyl.

39. A compound of claim 18, having the formula:



wherein  $R^{2c}$  is halogen, cyano or nitro;  $R^{2b}$  is selected from  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^e$ ,  $-OR^c$ ,  $-NR^cR^d$ ,  $-NR^cS(O)_2R^e$  and  $-NR^dC(O)R^c$ ;  $R^{3a}$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl and  $C_{3-6}$  cycloalkyl;  $R^{3c}$  is selected from the group consisting of  $NH_2$ ,  $CF_3$ ,  $SCH_3$  and  $Y$ ; and  $R^{3b}$  is chloro or bromo.


40. A compound of claim 18, having the formula:



3 wherein  $R^{2c}$  is halogen, cyano or nitro;  $R^{2b}$  is selected from  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^c$ ,  
4  $-OR^c$ ,  $-NR^cR^d$ ,  $-NR^cS(O)_2R^c$  and  $-NR^dC(O)R^c$ ;  $R^{3a}$  is selected from the group consisting of  
5  $NH_2$ ,  $CF_3$ ,  $SCH_3$  and  $Y$ ;  $R^{3b}$  is chloro or bromo; and  $R^{3c}$  is selected from the group consisting  
6 of  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl and  $C_{3-6}$  cycloalkyl wherein the aliphatic portions of  $R^{3c}$  are  
7 optionally substituted with a member selected from the group consisting of  $-OH$ ,  $-OR^o$ ,  
8  $-OC(O)NHR^o$ ,  $-OC(O)N(R^o)_2$ ,  $-SH$ ,  $-SR^o$ ,  $-S(O)R^o$ ,  $-S(O)_2R^o$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^o$ ,  
9  $-S(O)_2N(R^o)_2$ ,  $-NHS(O)_2R^o$ ,  $-NR^oS(O)_2R^o$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^o$ ,  $-C(O)N(R^o)_2$ ,  $-C(O)R^o$ ,  
10  $-NHC(O)R^o$ ,  $-NR^oC(O)R^o$ ,  $-NHC(O)NH_2$ ,  $-NR^oC(O)NH_2$ ,  $-NR^oC(O)NHR^o$ ,  $-NHC(O)NHR^o$ ,  
11  $-NR^oC(O)N(R^o)_2$ ,  $-NHC(O)N(R^o)_2$ ,  $-CO_2H$ ,  $-CO_2R^o$ ,  $-NHCO_2R^o$ ,  $-NR^oCO_2R^o$ ,  $-CN$ ,  $-NO_2$ ,  
12  $-NH_2$ ,  $-NHR^o$ ,  $-N(R^o)_2$ ,  $-NR^oS(O)NH_2$  and  $-NR^oS(O)_2NHR^o$ .

1 41. A compound of claim 40, wherein each  $R^1$ , when present, is selected  
2 from the group consisting of  $-CO_2H$  and  $C_{1-4}$  alkyl, optionally substituted with a member  
3 selected from the group consisting of  $-OH$ ,  $-OR^m$ ,  $-S(O)_2R^m$ ,  $-CO_2H$  and  $-CO_2R^m$ .


1 42. A compound of claim 18, having the formula:



2  
3 wherein  $R^{2c}$  is halogen, cyano or nitro;  $R^{2b}$  is selected from  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^c$ ,  
4  $-OR^c$ ,  $-NR^cR^d$ ,  $-NR^cS(O)_2R^c$  and  $-NR^dC(O)R^c$ ;  $R^{3a}$  is selected from the group consisting of  
5  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl and  $C_{3-6}$  cycloalkyl, wherein the aliphatic portions of  $R^{3a}$  are  
6 optionally substituted with a member selected from the group consisting of  $-OH$ ,  $-OR^o$ ,  
7  $-OC(O)NHR^o$ ,  $-OC(O)N(R^o)_2$ ,  $-SH$ ,  $-SR^o$ ,  $-S(O)R^o$ ,  $-S(O)_2R^o$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^o$ ,  
8  $-S(O)_2N(R^o)_2$ ,  $-NHS(O)_2R^o$ ,  $-NR^oS(O)_2R^o$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^o$ ,  $-C(O)N(R^o)_2$ ,  $-C(O)R^o$ ,  
9  $-NHC(O)R^o$ ,  $-NR^oC(O)R^o$ ,  $-NHC(O)NH_2$ ,  $-NR^oC(O)NH_2$ ,  $-NR^oC(O)NHR^o$ ,  $-NHC(O)NHR^o$ ,  
10  $-NR^oC(O)N(R^o)_2$ ,  $-NHC(O)N(R^o)_2$ ,  $-CO_2H$ ,  $-CO_2R^o$ ,  $-NHCO_2R^o$ ,  $-NR^oCO_2R^o$ ,  $-CN$ ,  $-NO_2$ ,  
11  $-NH_2$ ,  $-NHR^o$ ,  $-N(R^o)_2$ ,  $-NR^oS(O)NH_2$  and  $-NR^oS(O)_2NHR^o$ ;  $R^{3c}$  is selected from the group  
12 consisting of  $NH_2$ ,  $CF_3$ ,  $SCH_3$  and  $Y$ ; and  $R^{3b}$  is chloro or bromo.

1 43. A compound of claim 42, wherein each  $R^1$ , when present, is selected  
2 from the group consisting of  $-CO_2H$  and  $C_{1-4}$  alkyl, optionally substituted with a member  
3 selected from the group consisting of  $-OH$ ,  $-OR^m$ ,  $-S(O)_2R^m$ ,  $-CO_2H$  and  $-CO_2R^m$ .


44. A compound of claim 18, having the formula:



wherein  $R^{2a}$  is other than hydrogen;  $R^{2c}$  is halogen, cyano or nitro;  $R^{2d}$  is selected from  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^e$ ,  $-OR^c$ ,  $-NR^cR^d$ ,  $-NR^cS(O)_2R^e$  and  $-NR^dC(O)R^c$ ;  $R^{3a}$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl and  $C_{3-6}$  cycloalkyl, optionally substituted with a member selected from the group consisting of  $-OH$ ,  $-OR^o$ ,  $-OC(O)NHR^o$ ,  $-OC(O)N(R^o)_2$ ,  $-SH$ ,  $-SR^o$ ,  $-S(O)R^o$ ,  $-S(O)_2R^o$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^o$ ,  $-S(O)_2N(R^o)_2$ ,  $-NHS(O)_2R^o$ ,  $-NR^oS(O)_2R^o$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^o$ ,  $-C(O)N(R^o)_2$ ,  $-C(O)R^o$ ,  $-NHC(O)R^o$ ,  $-NR^oC(O)R^o$ ,  $-NHC(O)NH_2$ ,  $-NR^oC(O)NH_2$ ,  $-NR^oC(O)NHR^o$ ,  $-NHC(O)NHR^o$ ,  $-NR^oC(O)N(R^o)_2$ ,  $-NHC(O)N(R^o)_2$ ,  $-CO_2H$ ,  $-CO_2R^o$ ,  $-NHCO_2R^o$ ,  $-NR^oCO_2R^o$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NHR^o$ ,  $-N(R^o)_2$ ,  $-NR^oS(O)NH_2$  and  $-NR^oS(O)_2NHR^o$ ;  $R^{3b}$  is chloro or bromo; and  $R^{3c}$  is selected from the group consisting of  $NH_2$ ,  $CF_3$ ,  $SCH_3$  and  $Y$ .

45. A compound of claim 44, wherein each  $R^1$ , when present, is selected from the group consisting of  $-CO_2H$  and  $C_{1-4}$  alkyl, optionally substituted with a member selected from the group consisting of  $-OH$ ,  $-OR^m$ ,  $-S(O)_2R^m$ ,  $-CO_2H$  and  $-CO_2R^m$ .

46. A compound of claim 18, having the formula:



wherein  $R^{2a}$  is other than hydrogen;  $R^{2c}$  is halogen, cyano or nitro;  $R^{2d}$  is  $-SR^c$ ,  $-O-X^2-OR^c$ ,  $-X^2-OR^c$ ,  $-R^e$ ,  $-OR^c$ ,  $-NR^cR^d$ ,  $-NR^cS(O)_2R^e$  and  $-NR^dC(O)R^c$ ;  $R^{3a}$  is selected from the group consisting of  $NH_2$ ,  $CF_3$ ,  $SCH_3$  and  $Y$ ;  $R^{3b}$  is chloro or bromo; and  $R^{3c}$  is selected from the group consisting of  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl and  $C_{3-6}$  cycloalkyl, optionally substituted with a member selected from the group consisting of  $-OH$ ,  $-OR^o$ ,  $-OC(O)NHR^o$ ,  $-OC(O)N(R^o)_2$ ,  $-SH$ ,  $-SR^o$ ,  $-S(O)R^o$ ,  $-S(O)_2R^o$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^o$ ,  $-S(O)_2N(R^o)_2$ ,  $-NHS(O)_2R^o$ ,  $-NR^oS(O)_2R^o$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^o$ ,  $-C(O)N(R^o)_2$ ,  $-C(O)R^o$ ,  $-NHC(O)R^o$ ,  $-NR^oC(O)R^o$ ,

10 -NHC(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NH<sub>2</sub>, -NR<sup>o</sup>C(O)NHR<sup>o</sup>, -NHC(O)NHR<sup>o</sup>, -NR<sup>o</sup>C(O)N(R<sup>o</sup>)<sub>2</sub>,  
11 -NHC(O)N(R<sup>o</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>o</sup>, -NHCO<sub>2</sub>R<sup>o</sup>, -NR<sup>o</sup>CO<sub>2</sub>R<sup>o</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>o</sup>,  
12 -N(R<sup>o</sup>)<sub>2</sub>, -NR<sup>o</sup>S(O)NH<sub>2</sub> and -NR<sup>o</sup>S(O)<sub>2</sub>NHR<sup>o</sup>.

1                   47.     A compound of claim 46, wherein each R<sup>1</sup>, when present, is selected  
2 from the group consisting of -CO<sub>2</sub>H and C<sub>1-4</sub> alkyl, optionally substituted with a member  
3 selected from the group consisting of -OH, -OR<sup>m</sup>, -S(O)<sub>2</sub>R<sup>m</sup>, -CO<sub>2</sub>H and -CO<sub>2</sub>R<sup>m</sup>.

1                   48.     A compound of claim 30, wherein at least one of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is  
2 selected from the group consisting of halogen and C<sub>1-4</sub> haloalkyl.

1                   49.     A compound of claim 48, wherein each of R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> is other  
2 than hydrogen.

1                   50.     A compound of claim 18, wherein m is 0 or 1; R<sup>1</sup>, when present, is C<sub>1-2</sub>  
2 alkyl, optionally substituted with a member selected from the group consisting of -OH, -OR<sup>m</sup>,  
3 -S(O)<sub>2</sub>R<sup>m</sup>, -CO<sub>2</sub>H and -CO<sub>2</sub>R<sup>m</sup>; R<sup>2a</sup> is selected from H, CH<sub>3</sub> and halogen; R<sup>2b</sup> is H; R<sup>2c</sup> is  
4 selected from H, Cl and Br; R<sup>2d</sup> is selected from OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, NHCH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub> and  
5 CH<sub>3</sub>; R<sup>2e</sup> is H, such that at least one of R<sup>2a</sup> and R<sup>2c</sup> is other than H; R<sup>3b</sup> is Cl or Br; one of R<sup>3a</sup>  
6 and R<sup>3c</sup> is cyclopropyl, CF<sub>3</sub>, or methyl, optionally substituted with NH<sub>2</sub>, OH or OCH<sub>3</sub>, and  
7 the other of R<sup>3a</sup> and R<sup>3c</sup> is selected from the group consisting of CF<sub>3</sub>, Br, CH<sub>3</sub>, -CO<sub>2</sub>CH<sub>3</sub>,  
8 -CO<sub>2</sub>Et, -N(CH<sub>3</sub>)<sub>2</sub>, -NH<sub>2</sub>, ethyl, isopropyl, substituted phenyl and substituted or unsubstituted  
9 thienyl.


1                   51.     A compound of claim 18, wherein the phenyl ring bearing R<sup>2a</sup> through  
2 R<sup>2e</sup> is selected from the substituted phenyl groups provided in Figures 1A and 1B.

1                   52.     A compound of claim 18, wherein the pyrazole ring bearing R<sup>3a</sup>  
2 through R<sup>3c</sup> is selected from the substituted pyrazole groups provided in Figures 2A, 2B, 2C,  
3 2D, 2E, 2F and 3.

1                   53.     A pharmaceutical composition comprising a pharmaceutically  
2 acceptable excipient and a compound of claim 1.

1                   54.     A method of treating CCR1-mediated diseases or conditions  
2 comprising administering to a subject in need thereof a therapeutically effective amount of a  
3 compound having the formula:





or a pharmaceutically acceptable salt or N-oxide thereof, wherein

the subscript n is an integer of from 1 to 2;

the subscript m is an integer of from 0 to 10;

each R<sup>1</sup> is a substituent independently selected from the group consisting of C<sub>1-8</sub> alkyl,

C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, -COR<sup>a</sup>, -CO<sub>2</sub>R<sup>a</sup>,

-CONR<sup>a</sup>R<sup>b</sup>, -NR<sup>a</sup>COR<sup>b</sup>, -SO<sub>2</sub>R<sup>a</sup>, -X<sup>1</sup>COR<sup>a</sup>, -X<sup>1</sup>CO<sub>2</sub>R<sup>a</sup>, -X<sup>1</sup>CONR<sup>a</sup>R<sup>b</sup>,

-X<sup>1</sup>NR<sup>a</sup>COR<sup>b</sup>, -X<sup>1</sup>SO<sub>2</sub>R<sup>a</sup>, -X<sup>1</sup>SO<sub>2</sub>NR<sup>a</sup>R<sup>b</sup>, -X<sup>1</sup>NR<sup>a</sup>R<sup>b</sup>, -X<sup>1</sup>OR<sup>a</sup>, wherein X<sup>1</sup> is a

member selected from the group consisting of C<sub>1-4</sub> alkylene, C<sub>2-4</sub> alkenylene and

C<sub>2-4</sub> alkynylene and each R<sup>a</sup> and R<sup>b</sup> is independently selected from the group

consisting of hydrogen, C<sub>1-8</sub> alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl and aryl-

C<sub>1-4</sub>alkyl, and wherein the aliphatic portions of each of said R<sup>1</sup> substituents is

optionally substituted with from one to three members selected from the group

consisting of -OH, -OR<sup>m</sup>, -OC(O)NHR<sup>m</sup>, -OC(O)N(R<sup>m</sup>)<sub>2</sub>, -SH, -SR<sup>m</sup>, -S(O)R<sup>m</sup>,

-S(O)<sub>2</sub>R<sup>m</sup>, -SO<sub>2</sub>NH<sub>2</sub>, -S(O)<sub>2</sub>NHR<sup>m</sup>, -S(O)<sub>2</sub>N(R<sup>m</sup>)<sub>2</sub>, -NHS(O)<sub>2</sub>R<sup>m</sup>, -NR<sup>m</sup>S(O)<sub>2</sub>R<sup>m</sup>,

-C(O)NH<sub>2</sub>, -C(O)NHR<sup>m</sup>, -C(O)N(R<sup>m</sup>)<sub>2</sub>, -C(O)R<sup>m</sup>, -NHC(O)R<sup>m</sup>, -NR<sup>m</sup>C(O)R<sup>m</sup>,

-NHC(O)NH<sub>2</sub>, -NR<sup>m</sup>C(O)NH<sub>2</sub>, -NR<sup>m</sup>C(O)NHR<sup>m</sup>, -NHC(O)NHR<sup>m</sup>,

-NR<sup>m</sup>C(O)N(R<sup>m</sup>)<sub>2</sub>, -NHC(O)N(R<sup>m</sup>)<sub>2</sub>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>m</sup>, -NHCO<sub>2</sub>R<sup>m</sup>, -NR<sup>m</sup>CO<sub>2</sub>R<sup>m</sup>,

-CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>m</sup>, -N(R<sup>m</sup>)<sub>2</sub>, -NR<sup>m</sup>S(O)NH<sub>2</sub> and -NR<sup>m</sup>S(O)<sub>2</sub>NHR<sup>m</sup>,

wherein each R<sup>m</sup> is independently an unsubstituted C<sub>1-6</sub> alkyl;

Ar<sup>1</sup> is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrazinyl,

pyridazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxaliny and purinyl, each of

which is optionally substituted with from one to five R<sup>2</sup> substituents

independently selected from the group consisting of halogen, -OR<sup>c</sup>, -OC(O)R<sup>c</sup>, -

NR<sup>c</sup>R<sup>d</sup>, -SR<sup>c</sup>, -R<sup>c</sup>, -CN, -NO<sub>2</sub>, -CO<sub>2</sub>R<sup>c</sup>, -CONR<sup>c</sup>R<sup>d</sup>, -C(O)R<sup>c</sup>, -OC(O)NR<sup>c</sup>R<sup>d</sup>, -

NR<sup>d</sup>C(O)R<sup>c</sup>, -NR<sup>d</sup>C(O)<sub>2</sub>R<sup>c</sup>, -NR<sup>c</sup>-C(O)NR<sup>c</sup>R<sup>d</sup>, -NH-C(NH<sub>2</sub>)=NH,

-NR<sup>c</sup>C(NH<sub>2</sub>)=NH, -NH-C(NH<sub>2</sub>)=NR<sup>c</sup>, -NH-C(NHR<sup>c</sup>)=NH, -S(O)R<sup>c</sup>, -S(O)<sub>2</sub>R<sup>c</sup>, -

NR<sup>c</sup>S(O)<sub>2</sub>R<sup>c</sup>, -S(O)<sub>2</sub>NR<sup>c</sup>R<sup>d</sup>, -N<sub>3</sub>, -X<sup>2</sup>OR<sup>c</sup>, -O-X<sup>2</sup>OR<sup>c</sup>, -X<sup>2</sup>OC(O)R<sup>c</sup>, -X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>,

-O-X<sup>2</sup>NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>SR<sup>c</sup>, -X<sup>2</sup>CN, -X<sup>2</sup>NO<sub>2</sub>, -X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, -O-X<sup>2</sup>CO<sub>2</sub>R<sup>c</sup>, -X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>,

-O-X<sup>2</sup>CONR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>C(O)R<sup>c</sup>, -X<sup>2</sup>OC(O)NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>NR<sup>d</sup>C(O)R<sup>c</sup>, -X<sup>2</sup>NR<sup>d</sup>C(O)<sub>2</sub>R<sup>c</sup>,

-X<sup>2</sup>NR<sup>c</sup>C(O)NR<sup>c</sup>R<sup>d</sup>, -X<sup>2</sup>NH-C(NH<sub>2</sub>)=NH, -X<sup>2</sup>NR<sup>c</sup>C(NH<sub>2</sub>)=NH, -X<sup>2</sup>NH-

$C(NH_2)=NR^c$ ,  $-X^2NH-C(NHR^c)=NH$ ,  $-X^2S(O)R^c$ ,  $-X^2S(O)_2R^c$ ,  $-X^2NR^cS(O)_2R^c$ ,  
 $-X^2S(O)_2NR^cR^d$ ,  $-X^2N_3$ ,  $-NR^d-X^2OR^c$ ,  $-NR^d-X^2NR^cR^d$ ,  $-NR^d-X^2CO_2R^c$ , and  
 $-NR^d-X^2CONR^cR^d$ , wherein  $X^2$  is a member selected from the group consisting of  
 $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene and  $C_{2-4}$  alkynylene and each  $R^c$  and  $R^d$  is  
independently selected from hydrogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  
 $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl,  
or optionally  $R^c$  and  $R^d$  when attached to the same nitrogen atom can be combined  
with the nitrogen atom to form a five or six-membered ring having from 0 to 2  
additional heteroatoms as ring members; and each  $R^e$  is independently selected  
from the group consisting of  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-8}$   
alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl, and  
each of  $R^c$ ,  $R^d$  and  $R^e$  is optionally further substituted with from one to three  
members selected from the group consisting of  $-OH$ ,  $-OR^n$ ,  $-OC(O)NHR^n$ ,  
 $-OC(O)N(R^n)_2$ ,  $-SH$ ,  $-SR^n$ ,  $-S(O)R^n$ ,  $-S(O)_2R^n$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^n$ ,  
 $-S(O)_2N(R^n)_2$ ,  $-NHS(O)_2R^n$ ,  $-NR^nS(O)_2R^n$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^n$ ,  $-C(O)N(R^n)_2$ ,  
 $-C(O)R^n$ ,  $-NHC(O)R^n$ ,  $-NR^nC(O)R^n$ ,  $-NHC(O)NH_2$ ,  $-NR^nC(O)NH_2$ ,  
 $-NR^nC(O)NHR^n$ ,  $-NHC(O)NHR^n$ ,  $-NR^nC(O)N(R^n)_2$ ,  $-NHC(O)N(R^n)_2$ ,  $-CO_2H$ ,  
 $-CO_2R^n$ ,  $-NHCO_2R^n$ ,  $-NR^nCO_2R^n$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NHR^n$ ,  $-N(R^n)_2$ ,  
 $-NR^nS(O)NH_2$  and  $-NR^nS(O)_2NHR^n$ , wherein each  $R^n$  is independently an  
unsubstituted  $C_{1-6}$  alkyl;

HAr is a heteroaryl group selected from the group consisting of pyrazolyl, imidazolyl,  
triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxathiadiazolyl, pyrrolyl,  
thiazolyl, isothiazolyl, benzimidazolyl, benzopyrazolyl and benzotriazolyl, each of  
which is substituted with from one to five  $R^3$  substituents independently selected  
from the group consisting of halogen,  $-OR^f$ ,  $-OC(O)R^f$ ,  $-NR^fR^g$ ,  $-SR^f$ ,  $-R^h$ ,  $-CN$ ,  
 $-NO_2$ ,  $-CO_2R^f$ ,  $-CONR^fR^g$ ,  $-C(O)R^f$ ,  $-OC(O)NR^fR^g$ ,  $-NR^gC(O)R^f$ ,  $-NR^gC(O)_2R^h$ ,  
 $-NR^f-C(O)NR^fR^g$ ,  $-NH-C(NH_2)=NH$ ,  $-NR^hC(NH_2)=NH$ ,  $-NH-C(NH_2)=NR^h$ ,  $-NH-$   
 $C(NHR^h)=NH$ ,  $-S(O)R^h$ ,  $-S(O)_2R^h$ ,  $-NR^fS(O)_2R^h$ ,  $-S(O)_2NR^fR^g$ ,  $-NR^fS(O)_2NR^fR^g$ ,  
 $-N_3$ ,  $-X^3OR^f$ ,  $-X^3OC(O)R^f$ ,  $-X^3NR^fR^g$ ,  $-X^3SR^f$ ,  $-X^3CN$ ,  $-X^3NO_2$ ,  $-X^3CO_2R^f$ ,  
 $-X^3CONR^fR^g$ ,  $-X^3C(O)R^f$ ,  $-X^3OC(O)NR^fR^g$ ,  $-X^3NR^gC(O)R^f$ ,  $-X^3NR^gC(O)_2R^h$ ,  
 $-X^3NR^f-C(O)NR^fR^g$ ,  $-X^3NH-C(NH_2)=NH$ ,  $-X^3NR^hC(NH_2)=NH$ ,  $-X^3NH-$   
 $C(NH_2)=NR^h$ ,  $-X^3NH-C(NHR^h)=NH$ ,  $-X^3S(O)R^h$ ,  $-X^3S(O)_2R^h$ ,  $-X^3NR^fS(O)_2R^h$ ,  
 $-X^3S(O)_2NR^fR^g$ ,  $-Y$ ,  $-X^3Y$ ,  $-X^3N_3$ ,  $-O-X^3OR^f$ ,  $-O-X^3NR^fR^g$ ,  $-O-X^3CO_2R^f$ ,  
 $-O-X^3CONR^fR^g$ ,  $-NR^g-X^3OR^f$ ,  $-NR^g-X^3NR^fR^g$ ,  $-NR^g-X^3CO_2R^f$ , and

$-NR^g-X^3CONR^fR^g$ , wherein Y is a five or six-membered aryl, heteroaryl or heterocyclic ring, optionally substituted with from one to three substituents selected from the group consisting of halogen,  $-OR^f$ ,  $-NR^fR^g$ ,  $-R^h$ ,  $-SR^f$ ,  $-CN$ ,  $-NO_2$ ,  $-CO_2R^f$ ,  $-CONR^fR^g$ ,  $-C(O)R^f$ ,  $-NR^gC(O)R^f$ ,  $-S(O)R^h$ ,  $-S(O)_2R^h$ ,  $-NR^fS(O)_2R^h$ ,  $-S(O)_2NR^fR^g$ ,  $-X^3OR^f$ ,  $-X^3NR^fR^g$ ,  $-X^3NR^fS(O)_2R^h$  and  $-X^3S(O)_2NR^fR^g$ , and wherein each  $X^3$  is independently selected from the group consisting of  $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene and  $C_{2-4}$  alkynylene and each  $R^f$  and  $R^g$  is independently selected from hydrogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a five or six-membered ring having from 0 to 2 additional heteroatoms as ring members, and each  $R^h$  is independently selected from the group consisting of  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl, wherein the aliphatic portions of  $R^f$ ,  $R^g$  and  $R^h$  is optionally further substituted with from one to three members selected from the group consisting of  $-OH$ ,  $-OR^o$ ,  $-OC(O)NHR^o$ ,  $-OC(O)N(R^o)_2$ ,  $-SH$ ,  $-SR^o$ ,  $-S(O)R^o$ ,  $-S(O)_2R^o$ ,  $-SO_2NH_2$ ,  $-S(O)_2NHR^o$ ,  $-S(O)_2N(R^o)_2$ ,  $-NHS(O)_2R^o$ ,  $-NR^oS(O)_2R^o$ ,  $-C(O)NH_2$ ,  $-C(O)NHR^o$ ,  $-C(O)N(R^o)_2$ ,  $-C(O)R^o$ ,  $-NHC(O)R^o$ ,  $-NR^oC(O)R^o$ ,  $-NHC(O)NH_2$ ,  $-NR^oC(O)NH_2$ ,  $-NR^oC(O)NHR^o$ ,  $-NHC(O)NHR^o$ ,  $-NR^oC(O)N(R^o)_2$ ,  $-NHC(O)N(R^o)_2$ ,  $-CO_2H$ ,  $-CO_2R^o$ ,  $-NHCO_2R^o$ ,  $-NR^oCO_2R^o$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NHR^o$ ,  $-N(R^o)_2$ ,  $-NR^oS(O)NH_2$  and  $-NR^oS(O)_2NHR^o$ , wherein each  $R^o$  is independently an unsubstituted  $C_{1-6}$  alkyl;

$L^1$  is a linking group having from one to three main chain atoms selected from the group consisting of C, N, O and S and being optionally substituted with from one to three substituents selected from the group consisting of halogen, phenyl,  $-OR^i$ ,  $-OC(O)R^i$ ,  $-NR^iR^j$ ,  $-SR^i$ ,  $-R^k$ ,  $-CN$ ,  $-NO_2$ ,  $-CO_2R^i$ ,  $-CONR^iR^j$ ,  $-C(O)R^i$ ,  $-OC(O)NR^iR^j$ ,  $-NR^jC(O)R^i$ ,  $-NR^jC(O)_2R^k$ ,  $-X^4OR^i$ ,  $-X^4OC(O)R^i$ ,  $-X^4NR^iR^j$ ,  $-X^4SR^i$ ,  $-X^4CN$ ,  $-X^4NO_2$ ,  $-X^4CO_2R^i$ ,  $-X^4CONR^iR^j$ ,  $-X^4C(O)R^i$ ,  $-X^4OC(O)NR^iR^j$ ,  $-X^4NR^jC(O)R^i$  and  $-X^4NR^jC(O)_2R^k$ , wherein  $X^4$  is selected from the group consisting of  $C_{1-4}$  alkylene,  $C_{2-4}$  alkenylene and  $C_{2-4}$  alkynylene and each  $R^i$  and  $R^j$  is independently selected from hydrogen,  $C_{1-8}$  alkyl,  $C_{1-8}$  haloalkyl,  $C_{3-6}$  cycloalkyl,  $C_{2-8}$  alkenyl,  $C_{2-8}$  alkynyl, aryl, heteroaryl, aryl- $C_{1-4}$  alkyl, and aryloxy- $C_{1-4}$  alkyl, and each  $R^k$  is independently selected from the group consisting of  $C_{1-8}$

103 alkyl, C<sub>1-8</sub> haloalkyl, C<sub>3-6</sub> cycloalkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, aryl, heteroaryl,  
104 aryl-C<sub>1-4</sub> alkyl, and aryloxy-C<sub>1-4</sub> alkyl.

1 55. A method in accordance with claim 54, wherein said CCR1-mediated  
2 disease or condition is an inflammatory condition.

1 56. A method in accordance with claim 54, wherein said CCR1-mediated  
2 disease or condition is an immunoregulatory disorder.

1 57. A method in accordance with claim 54, wherein said CCR1-mediated  
2 disease or condition is selected from the group consisting of rheumatoid arthritis, multiple  
3 sclerosis, transplant rejection, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel  
4 disease, food allergy and encephalomyelitis.

1 58. A method in accordance with claim 54, wherein said administering is  
2 oral, parenteral, rectal, transdermal, sublingual, nasal or topical.

1 59. A method in accordance with claim 54, wherein said compound is  
2 administered in combination with an anti-inflammatory or analgesic agent.